Sulfinpyrazone in the prevention of sudden death after myocardial infarction

The New England Journal of Medicine
Anturane Reinfarction Trial Research Group

Abstract

We report the results of a randomized double-blind, multicenter trial comparing sulfinpyrazone (200 mg four times a day) and a placebo in the prevention of cardiac mortality among 1558 patients followed for an average of 16 months, beginning 25 to 35 days after a documented myocardial infarction. All but one of the 106 deaths in the group were cardiac; 59 were sudden. The reduction in cardiac mortality at 24 months in the sulfinpyrazone group was 32 per cent (P = 0.058), and the reduction in sudden death was 43 per cent (P = 0.041). The benefit of sulfinpyrazone was attributable entirely to a reduction in sudden death during the second through seventh months after infarction, when there were 35 cardiac deaths in the placebo group and 17 in the sulfinpyrazone group (P = 0.021); of these deaths, 24 in the placebo group and six in the sulfinpyrazone group were sudden cardiac deaths -- a sulfinpyrazone-induced 74 per cent reduction in the calculated mortality rate (P = 0.003). We conclude that sulfinpyrazone prevents sudden cardiac death during the high-risk period shortly after an acute myocardial infarction, but that there is no further apparent effect beyond the seventh month after infarction.

References

Aug 1, 1978·The American Journal of Cardiology·J T BiggerF M Weld
Feb 9, 1978·The New England Journal of Medicine·UNKNOWN Anturane Reinfarction Trial Research Group
Aug 1, 1968·American Journal of Public Health and the Nation's Health·E WeinblattR V Sager
Jun 1, 1960·The American Journal of Medicine·O W BEARDL G BERAN
Apr 30, 1964·The New England Journal of Medicine·S PELL, C A D ALONZO

❮ Previous
Next ❯

Citations

Mar 29, 2002·Journal of Applied Toxicology : JAT·G S BehonickS I Baskin
Sep 27, 2002·Statistics in Medicine·Jacobus Lubsen, Bridget-Anne Kirwan
Jan 1, 1983·European Journal of Clinical Pharmacology·S L ChoudhuryD B Morgan
Jan 1, 1983·European Journal of Clinical Pharmacology·B RosenkranzJ C Frölich
Jan 1, 1986·European Journal of Clinical Pharmacology·L A FerraraM L Fasano
Nov 15, 1982·Klinische Wochenschrift·E WalterK Jüngling
Dec 1, 1989·Cardiovascular Drugs and Therapy·B Stein, V Fuster
Dec 17, 1993·Pharmacy World & Science : PWS·A Keyser
Dec 13, 1985·Pharmaceutisch Weekblad. Scientific Edition·E G LentjesC A Van Ginneken
Feb 24, 1984·Pharmaceutisch Weekblad. Scientific Edition·H K Nieuwenhuis, J J Sixma
Oct 20, 2001·Science and Engineering Ethics·David L DeMets
Apr 1, 1981·The American Journal of Cardiology·R BolliS E Epstein
Jan 16, 1981·European Journal of Pharmacology·I LepránL Szekeres
May 1, 1983·Progress in Cardiovascular Diseases·G J Goldman, A D Pichard
Sep 1, 1987·Progress in Cardiovascular Diseases·H F Weisman, B Healy
Dec 11, 1991·Controlled Clinical Trials·R P Schwarz
Jan 1, 1982·Prostaglandins, Leukotrienes, and Medicine·G J KelliherB E Soifer
Jan 1, 1987·Social Science & Medicine·M S Patel
Oct 1, 1989·Journal of the American College of Cardiology·B SteinJ H Chesebro
Mar 13, 2002·Lancet·Kenneth F Schulz, David A Grimes
Jul 19, 1980·Lancet·L FriedmanW Friedewald
May 31, 1980·Lancet
Dec 1, 1986·Journal of the American College of Cardiology·C E Hjemdahl-MonsenV Fuster
Jan 1, 1996·International Journal of Technology Assessment in Health Care·L A Bero, D Rennie
Jul 3, 1980·The New England Journal of Medicine·J C Cowan, E M Williams
Dec 18, 1980·The New England Journal of Medicine·A S Relman
Dec 18, 1980·The New England Journal of Medicine·R Temple, G W Pledger
Mar 19, 1981·The New England Journal of Medicine·P Meier
Apr 22, 1982·The New England Journal of Medicine·W B Hood
Apr 22, 1982·The New England Journal of Medicine
Nov 28, 1985·The New England Journal of Medicine·J A CairnsM G Myers
May 20, 1998·The American Journal of the Medical Sciences·M WallsW Stone
Aug 20, 2010·BMJ : British Medical Journal·Gloria CordobaPeter C Gøtzsche
Jan 1, 1981·Journal of Neurosurgery·S Wessler, S N Gitel
Jan 1, 1986·European Journal of Clinical Pharmacology·E G LentjesC A van Ginneken
Dec 31, 1997·Controlled Clinical Trials·D L DeMets
Sep 1, 1982·Controlled Clinical Trials·W T Friedewald, J A Schoenberger
Jan 1, 1981·Current Medical Research and Opinion·J A Tulloch, T C Marr

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.